On August 4, 2012, K-V Pharmaceutical Company and certain of its domestic subsidiaries filed voluntary petitions for Chapter 11 bankruptcy.

Under Chapter 11:

• We remain open for business.
• We will continue working to meet the needs of our customers, including providing Makena^® (hydroxyprogesterone caproate injection) and Evamist^® (estradiol transdermal spray) without interruption.
• As we proceed from this day forward, we intend to pay our employees and vendors for services and goods provided after the filing.

The Company is committed to communicating openly as we move through this process. This website is a resource to provide accurate and timely information to our customers, business partners, and shareholders.

A copy of the press release announcing the Company’s filing is attached here.

As part of our Chapter 11 case, K-V’s Claims Administrator Epiq Systems maintains a web-based resource where all documents from the Chapter 11 filing and process, including our Petition, can be found at http://dm.epiq11.com/KVD.

Customers and Healthcare Community K-V Pharmaceutical Company is committed to advancing the care of women by providing medications that meet FDA’s quality standards and delivering outstanding support to you and your patients. Thank you for choosing FDA’s quality standards for your patients. FDA-approved Makena® and Evamist® continue to be available for prescribing. We will continue working to meet the needs of our customers, including providing Makena® and Evamist®, without interruption. Please click here for a letter from our Chief Executive Officer, Greg Divis.

Business Partners and Vendors You have been an important partner in supporting our business, and we sincerely value our working relationship with you. K-V Pharmaceutical’s business partners and vendors can expect to be contacted by the Company’s Claims Administrator, Epiq Systems, with information on how to file claims. Meanwhile, you may find the following material informative regarding the Chapter 11 filing and process. Click here for a letter from our Chief Financial Officer, Tom McHugh. Click here for Frequently-Asked Questions (FAQ) for Business Partners/Vendors.

Shareholders We recognize that Shareholders have questions about K-V’s stock and the impact of a Chapter 11 filing. Click here for the Company’s transition of trading of Class A and Class B common shares to the OTC markets. Click here for Shareholder FAQs.